Neurological disorders affect hundreds of millions of people worldwide, and for many patients, existing treatments fall far short. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company, is working to change that with a pipeline targeting two significant areas of unmet neurological need: multiple sclerosis and the acute cognitive and physiological effects of alcohol intoxication.
Multiple sclerosis is one of the most common and debilitating neurological diseases affecting young adults. An estimated 2.9 million people are living with MS worldwide, with about one million in the United States. The disease is most often diagnosed between ages 20 and 50, with a mean age of 32 globally, and affects females at roughly twice the rate of males. Quantum BioPharma’s focus for MS is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Supporting Lucid-MS’s phase 2 development is an ongoing imaging collaboration with Massachusetts General Hospital.
In addition to MS, the company developed unbuzzd, a proprietary dietary supplement formulated to support alcohol metabolism and reduce the acute effects of intoxication and hangover. This two-pronged strategy addresses both chronic and acute neurological challenges, highlighting the company’s commitment to innovation in brain health.
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM.
MissionIR is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and a full array of tailored corporate communications solutions. For more information, please visit https://www.MissionIR.com. Please see full terms of use and disclaimers on the MissionIR website at https://www.MissionIR.com/Disclaimer.
MissionIR is powered by IBN.
